EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudieOpen Access · CC BY 4.0

Preimplantation genetic testing for aneuploidy mosaicism reporting lacks clinical predictive value for live birth in a multisite, double-blinded study with independent validation

Pavan Gill, Xin Tao, Yiping Zhan, Francesca Mulas, Christian Simon Ottolini, Ludovica Picchetta, Silvia Caroselli, Dhruti Babariya, Dagan Wells, Georgina Clark, Elena Fernandez Marcos, Carlos Marin Vallejo und 12 weitere

American Journal of Obstetrics and Gynecology · 2026-04 · 234 (4) · 1015-1041

DOI: 10.1016/j.ajog.2025.12.033 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Obstetrics and Gynecology, 2026-04. Verfasst von Pavan Gill und 23 weiteren Autor:innen. Beteiligte Einrichtung: IVIRMA, Clinical Research, Basking Ridge, NJ. Hauptthemen laut MEDLINE: Mosaicism, Preimplantation Diagnosis, Live Birth, Aneuploidy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Preimplantation genetic testing for aneuploidy is used to improve in vitro fertilization outcomes by identifying embryos with lethal chromosomal abnormalities that impair development or lead to pregnancy loss. The adoption of next-generation sequencing has enabled detection of intermediate copy number deviations, often interpreted as putative mosaicism, whose clinical significance remains uncertain. OBJECTIVE: To determine whether reporting putative mosaicism based on intermediate copy number improves the prediction of reproductive outcomes and should influence embryo selection in clinical practice. STUDY DESIGN: We conducted a large, multisite, double-blinded, nonselection study across US fertility clinics (February 2020-October 2022), including 9828 single-embryo transfers from 7564 in vitro fertilization cycles. Findings were independently validated using 5487 euploid single-embryo transfers from European clinics (May 2022-March 2024). Intermediate copy number status was unblinded only after embryo transfer, allowing unbiased comparison between embryos that would have been classified as euploid or mosaic with our platform. The primary outcome for investigation in the study was live birth rate, defined as delivery after 24 weeks (gestational age). RESULTS: After unblinding the intermediate copy number status post-transfer, 84.7% (n=8328) of embryos were negative for intermediate copy number (euploid), while 8.8% (n=864) exhibited segmental intermediate copy number and 5.6% (n=562) showed whole-chromosome intermediate copy number within the current clinical and laboratory setting. A modest but statistically significant difference in live birth rate was observed between euploid embryos and those with intermediate copy number (60.0% vs 53.2%; adjusted odds ratio, 0.79; 95% confidence interval, 0.70-0.89), primarily driven by the small subset of embryos with high-level intermediate copy number (P .05). Miscarriage, obstetric, and neonatal outcomes were comparable across groups. CONCLUSION: Although the presence of high-level intermediate copy number in the trophectoderm biopsy was associated with a modest reduction in live birth rate, because of its low incidence and limited effect size, mosaic reporting did not contribute to a meaningful improvement in clinical outcomes. In our clinical and laboratory setting, reporting putative mosaicism provides no clinical benefit and should not guide embryo selection in routine in vitro fertilization practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MosaicismPreimplantation DiagnosisLive BirthAneuploidyGenetic TestingHumansFemalePregnancyDouble-Blind MethodAdultPredictive Value of TestsFertilization in VitroSingle Embryo TransferEmbryo Transfer

Stichwörter der Autor:innen

PGT-APGT-A reportingclinical predictive valueclinical utilitydouble-blinded studyembryomosaicism

Autor:innen und Institutionen

  • IVIRMA, Clinical Research, Basking Ridge, NJ.
  • Juno Genetics, Genetic Lab, Basking Ridge, NJ.
  • Juno Genetics, Reproductive Genetics, Rome, Italy.
  • Juno Genetics, Reproductive Genetics, Rome, Italy; University College London- Institute for Women's Health, Department of Maternal and Fetal Medicine, London, UK.
  • Juno Genetics, Reproductive Genetics, Rome, Italy; Department of Department of Bioscience and Agro-Food and Environmental Technology, University of Teramo, Teramo, Italy.
  • Juno Genetics, Oxford, UK.

Zitieren

APA

Gill, P., Tao, X., Zhan, Y., Mulas, F., Ottolini, C. S., Picchetta, L., Caroselli, S., Babariya, D., Wells, D., Clark, G., Fernandez Marcos, E., Marin Vallejo, C., Jobanputra, V., Werner, M., Scott, R., Molinaro, T., Pla Victori, J., Vergara Bravo, V., Requena Miranda, A., …, & Capalbo, A. (2026). Preimplantation genetic testing for aneuploidy mosaicism reporting lacks clinical predictive value for live birth in a multisite, double-blinded study with independent validation. American Journal of Obstetrics and Gynecology, 234(4), 1015-1041. https://doi.org/10.1016/j.ajog.2025.12.033

Vancouver

Gill P, Tao X, Zhan Y, Mulas F, Ottolini CS, Picchetta L, et al. Preimplantation genetic testing for aneuploidy mosaicism reporting lacks clinical predictive value for live birth in a multisite, double-blinded study with independent validation. American Journal of Obstetrics and Gynecology. 2026;234(4):1015-1041. doi:10.1016/j.ajog.2025.12.033

BibTeX
@article{Gill2026,
  author = {Gill, Pavan and Tao, Xin and Zhan, Yiping and Mulas, Francesca and Ottolini, Christian Simon and Picchetta, Ludovica and Caroselli, Silvia and Babariya, Dhruti and Wells, Dagan and Clark, Georgina and Fernandez Marcos, Elena and Marin Vallejo, Carlos and Jobanputra, Vaidehi and Werner, Marie and Scott, Richard and Molinaro, Thomas and Pla Victori, Josep and Vergara Bravo, Vanessa and Requena Miranda, Antonio and García Velasco, Juan Antonio and Pellicer, Antonio and Mounts, Emily and Jalas, Chaim and Capalbo, Antonio},
  title = {Preimplantation genetic testing for aneuploidy mosaicism reporting lacks clinical predictive value for live birth in a multisite, double-blinded study with independent validation},
  journal = {American Journal of Obstetrics and Gynecology},
  year = {2026},
  volume = {234},
  number = {4},
  pages = {1015--1041},
  doi = {10.1016/j.ajog.2025.12.033}
}
Kostenlos starten →